Page 745 - Bloomberg/reuters

Prashant Kumar, tasked to lead YES Bank's revival, braces for Covid impact

Yes Bank returned to profit in the quarter ended September and Kumar made provisions for potential covid-related losses

RBI encourages investment in sovereign bonds as part of liquidity measures

The pivot from RBI will help the government, which has said it will sell 1.1 trillion rupees more debt for the fiscal half ending in March

Mike Pence's chief of staff, other close aides test positive for Covid-19

Asked why the diagnoses hadn't been publicly revealed by the White House, Meadows said 'it's personal information' and that 'it's not something we usually do

China is reconsidering its global strategy for yuan, says official

Hurdles for yuan's internationalisation to be removed; move to ensure steady liberalisation of capital account

Alibaba Group's Jack Ma slams financial regulators' curbs on innovation

'World focussing only on risk control, not on development; Basel norms irrelevant for China's phase of development'

Kotak Mahindra Bank explores acquisition of IndusInd Bank

Kotak says no comments to offer; IndusInd CEO says promoters have denied the deal

Coronavirus isn't going away soon, world must reset hopes for economy

For decades, the world economy relied on central bankers and finance ministers to pull it out of crisis

Vedanta's $1.17 billion debt maturities prompt credit rating warnings

Moody's Investors Service last week put London-based Vedanta Resources under review for a possible downgrade, citing increased refinancing risk and large funding needs

To retire rich, don't leave too much to your kids

The retirement plan of Indians, like struggling middle-class people everywhere, now leans on spending on the education of their teenagers

Lee Kun-hee, who transformed Samsung into global conglomerate, dies at 78

Lee, who told employees to "change everything except your wife and children" during his drive to foster innovation and challenge rivals such as Sony Corp., was South Korea's richest person.\

Johnson & Johnson, AstraZeneca to resume trial for Covid-19 vaccine

Earlier, AstraZeneca said it had been cleared by the FDA to restart a trial that had been halted in the U.S. after a volunteer participating in a U.K. trial of the shot had fallen ill

US elections 2020: YouTube can't place all the political ads it gets

Campaigns have flooded YouTube with commercials in search of voters they may not be reaching on television

Swedish steelmaker SSAB looking at merger of Tata Steel Europe business

Steel producers in Europe are under pressure to consolidate, having been battered by weaker demand and global overcapacity

Ant Group lures Fidelity, T Rowe Price, UBS Asset for a piece of its IPO

Jack Ma's Chinese fintech giant is one of the most hotly anticipated IPOs in years, on course to make history by surpassing Saudi Aramco's record $29 billion share sale last year.

Tesla recalls 30,000 Model S and X cars in China over suspension problems

The news comes as the Chinese electric vehicle industry rebounds after an almost year-long slump.

India's valuation relative to EMs still less pricey than before, show data

While the S&P BSE Sensex Index is near the most expensive on record, its premium over the MSCI EM Index is only around 45 per cent

Valuation gaps: Growth stock rally leaves more room for disappointment

Since 2002, the MSCI AC World Growth Index has about doubled the return of its value counterpart, yet its relative earnings expectations have failed to grow at a similar pace

Over two-thirds of Indian Americans expected to vote for Biden, says survey

Indian American voters are less than 1 per cent of the US electorate, but the diaspora is seen as one of the most rapidly growing immigrant groups.

Westpac Banking to cut more than 150 jobs as bank exits China, India

Westpac will consolidate its overseas operations into three hubs -- Singapore, London and New York -- and institutional banking services will also be streamlined, Westpac said

Race for coronavirus cure hits reality as clinic complications mount

Regulators and drugmakers have faced questions about whether political pressure was overwhelming scientific rigor ahead of the presidential election on Nov. 3